Fibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights
August 02, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma
June 12, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., June 12, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
June 08, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., June 08, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell to Present at Inaugural Cell & Gene Exchange 2017
May 17, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., May 17, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights
May 10, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy
May 09, 2017 09:13 ET
|
Fibrocell Science, Inc.; Intrexon Corporation
EXTON, Pa. and GERMANTOWN, Md., May 09, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin...
Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
May 08, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., May 08, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights
May 03, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., May 03, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell to Present at 7th Annual World Orphan Drug Congress USA 2017 and 5th Annual Cell & Gene Therapy Investor Day
April 13, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., April 13, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Regains Compliance with NASDAQ Listing Requirements
March 28, 2017 08:00 ET
|
Fibrocell Science, Inc.
EXTON, Pa., March 28, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...